Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Dermatol Ther ; 31(5): e12685, 2018 09.
Article in English | MEDLINE | ID: mdl-30133929

ABSTRACT

Basal cell carcinoma (BCC) is one of the most frequent skin malignancies, with increasing incidence over the past years. Although the surgical excision is the gold-standard treatment, several other noninvasive therapies have also been developed for the management of these skin tumors, especially in the cases where a surgical intervention does not seem feasible. Imiquimod is an immunomodulatory agent, which has received approval in the topical treatment of superficial BCCs. With this short report, we present the case of a patient with multifocal pigmented BCCs, successfully treated with topical 5% imiquimod cream.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Basal Cell/drug therapy , Head and Neck Neoplasms/drug therapy , Imiquimod/therapeutic use , Neoplasms, Multiple Primary/drug therapy , Scalp , Skin Neoplasms/drug therapy , Administration, Cutaneous , Aged , Antineoplastic Agents/administration & dosage , Humans , Imiquimod/administration & dosage , Male , Skin Cream/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...